Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials.

IF 3.1 Q2 PERIPHERAL VASCULAR DISEASE High Blood Pressure & Cardiovascular Prevention Pub Date : 2024-10-30 DOI:10.1007/s40292-024-00682-w
Ikponmwosa Jude Ogieuhi, Kristen Callender, God-Dowell O Odukudu, Emeka Stanley Obi, Kudzaishe Muzofa, Adetola Emmanuel Babalola, Oshomoh Mark-Anthony Ugiomoh, Kenechukwu Hilary Umenzeakor, Adewunmi Akingbola, Charity Onetemizeh Ayoson, Emmanuel Uchenna Agbo, Moses Chukwuebuka Odoeke
{"title":"Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials.","authors":"Ikponmwosa Jude Ogieuhi, Kristen Callender, God-Dowell O Odukudu, Emeka Stanley Obi, Kudzaishe Muzofa, Adetola Emmanuel Babalola, Oshomoh Mark-Anthony Ugiomoh, Kenechukwu Hilary Umenzeakor, Adewunmi Akingbola, Charity Onetemizeh Ayoson, Emmanuel Uchenna Agbo, Moses Chukwuebuka Odoeke","doi":"10.1007/s40292-024-00682-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Elevated serum total cholesterol levels, very low-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, or a decreased serum high-density lipoprotein cholesterol concentration characterize dyslipidemia. Antisense Oligonucleotide therapy in dyslipidemia targets apolipoprotein B (ApoB), an essential component of low-density lipoprotein (LDL) associated with atherosclerosis development.</p><p><strong>Aim: </strong>This review aims to critically evaluate the efficacy and safety of this group of medications in mitigating dyslipidemia in at-risk individuals and its potential role in advancing personalized medicine in the management of dyslipidemias.</p><p><strong>Methods: </strong>A detailed search was conducted from multiple databases adhering to the PRISMA guidelines. Clinical trials and randomized controlled trials on antisense oligonucleotides for management of dyslipidemias were included, excluding non-English studies, case reports and all forms of reviews. Data was screened, with duplicates removed, and key findings were synthesized using a narrative approach.</p><p><strong>Results and conclusion: </strong>The potential of antisense oligonucleotides (ASOs) to treat dyslipidemia and other disorders has attracted much interest. Several studies and clinical trials have been conducted on the safety and tolerability of ASOs for dyslipidemia. Although statins are the mainstay management of hypercholesterolemia, there is evidence from clinical trials that ASOs can even be more effective with little to no side effects. Novel therapeutic approaches such as antisense oligonucleotides (ASOs) offer tailored therapeutic alternatives. ASOs such as Mipomersen and Volanesorsen provide additional treatment options for patients with inherited lipid abnormalities by lowering certain atherogenic lipoproteins such as apo B and ApoC-III, respectively.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"High Blood Pressure & Cardiovascular Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40292-024-00682-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Elevated serum total cholesterol levels, very low-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, or a decreased serum high-density lipoprotein cholesterol concentration characterize dyslipidemia. Antisense Oligonucleotide therapy in dyslipidemia targets apolipoprotein B (ApoB), an essential component of low-density lipoprotein (LDL) associated with atherosclerosis development.

Aim: This review aims to critically evaluate the efficacy and safety of this group of medications in mitigating dyslipidemia in at-risk individuals and its potential role in advancing personalized medicine in the management of dyslipidemias.

Methods: A detailed search was conducted from multiple databases adhering to the PRISMA guidelines. Clinical trials and randomized controlled trials on antisense oligonucleotides for management of dyslipidemias were included, excluding non-English studies, case reports and all forms of reviews. Data was screened, with duplicates removed, and key findings were synthesized using a narrative approach.

Results and conclusion: The potential of antisense oligonucleotides (ASOs) to treat dyslipidemia and other disorders has attracted much interest. Several studies and clinical trials have been conducted on the safety and tolerability of ASOs for dyslipidemia. Although statins are the mainstay management of hypercholesterolemia, there is evidence from clinical trials that ASOs can even be more effective with little to no side effects. Novel therapeutic approaches such as antisense oligonucleotides (ASOs) offer tailored therapeutic alternatives. ASOs such as Mipomersen and Volanesorsen provide additional treatment options for patients with inherited lipid abnormalities by lowering certain atherogenic lipoproteins such as apo B and ApoC-III, respectively.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
反义寡核苷酸治疗血脂异常:临床试验综述。
导言:血清总胆固醇、极低密度脂蛋白胆固醇、低密度脂蛋白胆固醇、甘油三酯水平升高或血清高密度脂蛋白胆固醇浓度降低是血脂异常的特征。反义寡核苷酸治疗血脂异常的靶点是载脂蛋白 B(ApoB),它是低密度脂蛋白(LDL)的重要组成部分,与动脉粥样硬化的发展有关。目的:本综述旨在批判性地评估这类药物在缓解高危人群血脂异常方面的疗效和安全性,以及其在推进个性化医疗管理血脂异常方面的潜在作用:方法:按照 PRISMA 指南对多个数据库进行了详细检索。纳入了有关反义寡核苷酸治疗血脂异常的临床试验和随机对照试验,排除了非英语研究、病例报告和各种形式的综述。对数据进行了筛选,删除了重复数据,并采用叙述法对主要研究结果进行了综合:反义寡核苷酸(ASO)治疗血脂异常和其他疾病的潜力引起了广泛关注。目前已就反义寡核苷酸治疗血脂异常的安全性和耐受性开展了多项研究和临床试验。虽然他汀类药物是治疗高胆固醇血症的主要药物,但临床试验的证据表明,ASO 甚至可以更有效,而且几乎没有副作用。反义寡核苷酸(ASO)等新型治疗方法提供了量身定制的替代治疗方案。Mipomersen 和 Volanesorsen 等 ASO 可分别降低某些致动脉粥样硬化脂蛋白(如载脂蛋白 B 和载脂蛋白 C-III),从而为遗传性血脂异常患者提供更多的治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.70
自引率
3.30%
发文量
57
期刊介绍: High Blood Pressure & Cardiovascular Prevention promotes knowledge, update and discussion in the field of hypertension and cardiovascular disease prevention, by providing a regular programme of independent review articles covering key aspects of the management of hypertension and cardiovascular diseases. The journal includes:   Invited ''State of the Art'' reviews.  Expert commentaries on guidelines, major trials, technical advances.Presentation of new intervention trials design.''Pros and Cons'' or round tables on controversial issues.Statements on guidelines from hypertension and cardiovascular scientific societies.Socio-economic issues.Cost/benefit in prevention of cardiovascular diseases.Monitoring of healthcare systems.News and views from the Italian Society of Hypertension (including abstracts).All manuscripts are subject to peer review by international experts. Letters to the editor are welcomed and will be considered for publication.
期刊最新文献
Juxtaposing Hypertension Guidelines: Are They Different? A Pragmatic Look to ESC and ESH Guidelines on (Arterial) Hypertension. Triple Therapy with Telmisartan, Amlodipine, and Rosuvastatin (TAR) Versus Telmisartan/Amlodipine (TA) and Telmisartan/Rosuvastatin (TR) Combinations in Hypertension and Dyslipidemia: A Systematic Review and Meta-analysis. Blood Pressure Control and Clinical Outcomes After Renal Denervation Through Irrigated Catheter Radiofrequency Ablation in Patients with Resistant Hypertension: A Case Series with Up to 10 Years of Follow-Up. Evidence for a Role of Gut Microbiota and Probiotics in Aneurysmal Pathogenesis and Possible Therapeutics: A Systematic Review of the Literature. Screening for Atrial Fibrillation During Routine Automated Blood Pressure Measurement in General Population Aged 65 Years and Above: EMENO National Epidemiological Survey in Greece.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1